Log in

ABIOMED Stock Forecast, Price & News

+0.79 (+0.30 %)
(As of 09/21/2020 12:00 AM ET)
Today's Range
Now: $265.86
50-Day Range
MA: $295.13
52-Week Range
Now: $265.86
Volume334,324 shs
Average Volume609,208 shs
Market Capitalization$11.98 billion
P/E Ratio76.62
Dividend YieldN/A
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company is involved in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump, a device for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.21 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
Current SymbolNASDAQ:ABMD



Sales & Book Value

Annual Sales$840.88 million
Cash Flow$5.29 per share
Book Value$23.64 per share


Net Income$203.01 million


Market Cap$11.98 billion
Next Earnings Date10/29/2020 (Estimated)
+0.79 (+0.30 %)
(As of 09/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

ABIOMED (NASDAQ:ABMD) Frequently Asked Questions

How has ABIOMED's stock been impacted by Coronavirus (COVID-19)?

ABIOMED's stock was trading at $151.13 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABMD shares have increased by 75.9% and is now trading at $265.86.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of ABIOMED?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for ABIOMED

When is ABIOMED's next earnings date?

ABIOMED is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for ABIOMED

How were ABIOMED's earnings last quarter?

ABIOMED, Inc. (NASDAQ:ABMD) released its earnings results on Thursday, August, 6th. The medical equipment provider reported $0.58 EPS for the quarter, beating analysts' consensus estimates of $0.20 by $0.38. The medical equipment provider earned $164.90 million during the quarter, compared to analyst estimates of $144.12 million. ABIOMED had a return on equity of 16.17% and a net margin of 19.88%. The company's revenue for the quarter was down 20.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.00 earnings per share.
View ABIOMED's earnings history

What price target have analysts set for ABMD?

8 brokerages have issued 12-month price objectives for ABIOMED's shares. Their forecasts range from $155.00 to $335.00. On average, they expect ABIOMED's share price to reach $236.75 in the next twelve months. This suggests that the stock has a possible downside of 10.9%.
View analysts' price targets for ABIOMED

Are investors shorting ABIOMED?

ABIOMED saw a drop in short interest in July. As of July 31st, there was short interest totaling 2,080,000 shares, a drop of 14.4% from the July 15th total of 2,430,000 shares. Based on an average daily volume of 438,200 shares, the short-interest ratio is presently 4.7 days. Approximately 4.7% of the company's shares are short sold.
View ABIOMED's Short Interest

Who are some of ABIOMED's key competitors?

What other stocks do shareholders of ABIOMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Netflix (NFLX), Square (SQ), Intuitive Surgical (ISRG), salesforce.com (CRM) and Adobe (ADBE).

Who are ABIOMED's key executives?

ABIOMED's management team includes the following people:
  • Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 52)
  • Dr. David M. Weber, Chief Operating Officer (Age 58)
  • Mr. Michael G. Howley, VP & GM of Global Sales (Age 55)
  • Mr. William J. Bolt, Exec. Officer (Age 67)
  • Mr. Ian McLeod, VP & Corp. Controller

What is ABIOMED's stock symbol?

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

Who are ABIOMED's major shareholders?

ABIOMED's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.68%), Bank of New York Mellon Corp (1.38%), Jackson Square Partners LLC (1.36%), William Blair Investment Management LLC (1.28%), Charles Schwab Investment Management Inc. (0.84%) and Blair William & Co. IL (0.81%). Company insiders that own ABIOMED stock include David M Weber, Dorothy E Puhy, Martin P Sutter, Michael G Howley, Michael R Minogue and Paul Thomas.
View institutional ownership trends for ABIOMED

Which major investors are selling ABIOMED stock?

ABMD stock was sold by a variety of institutional investors in the last quarter, including Baird Financial Group Inc., Vanguard Group Inc., Barclays PLC, Federated Hermes Inc., Rhenman & Partners Asset Management AB, Bank of America Corp DE, Assenagon Asset Management S.A., and Goldman Sachs Group Inc.. Company insiders that have sold ABIOMED company stock in the last year include Dorothy E Puhy, Martin P Sutter, Michael R Minogue, and Paul Thomas.
View insider buying and selling activity for ABIOMED

Which major investors are buying ABIOMED stock?

ABMD stock was acquired by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, William Blair Investment Management LLC, Blair William & Co. IL, Scout Investments Inc., Villere ST Denis J & Co. LLC, Jacobs Levy Equity Management Inc., Sumitomo Mitsui Trust Holdings Inc., and AQR Capital Management LLC.
View insider buying and selling activity for ABIOMED

How do I buy shares of ABIOMED?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ABIOMED's stock price today?

One share of ABMD stock can currently be purchased for approximately $265.86.

How big of a company is ABIOMED?

ABIOMED has a market capitalization of $11.98 billion and generates $840.88 million in revenue each year. The medical equipment provider earns $203.01 million in net income (profit) each year or $4.74 on an earnings per share basis. ABIOMED employs 1,536 workers across the globe.

What is ABIOMED's official website?

The official website for ABIOMED is www.abiomed.com.

How can I contact ABIOMED?

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.